USNA / USANA Health Sciences, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 28, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

USANA Health Sciences Reports Second Quarter 2025 Results and Reiterates Full-Year Outlook

USANA Health Sciences Reports Second Quarter 2025 Results and Reiterates Full-Year Outlook SALT LAKE CITY, July 22, 2025 (BUSINESS WIRE)—USANA Health Sciences, Inc.

$236 million

USANA Health Sciences, Inc. July 22, 2025 Q2 2025 Management Commentary Key Financial Results Three Months Ended June 28, 2025 June 29, 2024 Year-Over-Year Net Sales $236 $213 +11% Net Earnings $9.7 $10.4 -7% Diluted EPS $0.52 $0.54 -4% Adjusted Diluted EPS(1) $0.74 $0.54 +36% Adjusted EBITDA(2) $30 $27 +13% Direct Selling Active Customers 418,000 468,000 -11% Hiya Active Monthly Subscribers 200,4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 22, 2025 USANA HEALTH SCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 22, 2025 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 27, 2025 USANA HEALTH SCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 27, 2025 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission F

Third Amended and Restated Credit Agreement, dated as of June 27, 2025, by and among USANA Health Sciences, Inc. and certain of its subsidiaries, Bank of America, N.A. and the lenders party thereto.

COVERSHEET Please keep this cover sheet with the document through all distribution and communication.

Amended and Restated Security and Pledge Agreement, dated as of June 27, 2025, by and between USANA Health Sciences, Inc. and Bank of America, N.A.

Execution Version AMENDED AND RESTATED SECURITY AND PLEDGE AGREEMENT THIS AMENDED AND RESTATED SECURITY AND PLEDGE AGREEMENT (this “Agreement”) is entered into as of June 27, 2025, among USANA Health Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35024 A. Full title of the plan and the add

As filed with the Securities and Exchange Commission on May 21, 2025

As filed with the Securities and Exchange Commission on May 21, 2025 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) USANA Health Sciences, Inc.

Form of Performance Share Unit Agreement under the USANA Health Sciences, Inc. 2025 Equity Incentive Plan

PERFORMANCE SHARE UNIT AGREEMENT This Performance Share Unit Agreement (this “Agreement”) is made and entered into as of [●] (the “Grant Date”) by and between by and between USANA Health Sciences, Inc.

USANA Health Sciences, Inc. 2025 Equity Incentive Plan.

USANA HEALTH SCIENCES, INC. 2025 EQUITY INCENTIVE PLAN 1.Purpose; Eligibility. 1.1General Purpose. The name of this plan is the USANA Health Sciences, Inc. 2025 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (a) enable USANA Health Sciences, Inc., a Utah corporation (the “Company”), and any Affiliate to attract and retain the types of Employees, Consultants and Directors who w

Form of Stock Appreciation Right Agreement under the USANA Health Sciences, Inc. 2025 Equity Incentive Plan

STOCK APPRECIATION RIGHTS AGREEMENT This Stock Appreciation Rights Agreement (this “Agreement”) is made and entered into as of [●] by and between USANA Health Sciences, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 19, 2025 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission Fi

Form of Restricted Stock Unit Agreement under the USANA Health Sciences, Inc. 2025 Equity Incentive Plan

RESTRICTED STOCK UNIT AGREEMENT This Restricted Stock Unit Agreement (this “Agreement”) is made and entered into as of [●] (the “Grant Date”) by and between USANA Health Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Mark One) x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, For use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive

$250 million

USANA Health Sciences, Inc. April 22, 2025 Q1 2025 Management Commentary Key Financial Results Three Months Ended March 29, 2025 March 30, 2024 Year-over-Year Net Sales $250 $228 +10% Net Earnings $9.4 $16.5 -43% Diluted EPS $0.49 $0.86 -43% Adjusted Diluted EPS(1) $0.73 $0.86 -15% Adjusted EBITDA(2) $30 $33 -10% Direct Selling Active Customers 459,000 494,000 -7% Hiya Active Monthly Subscribers 2

USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook

USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook SALT LAKE CITY, April 22, 2025 (BUSINESS WIRE)—USANA Health Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 22, 2025 USANA HEALTH SCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 22, 2025 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Mark One) x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, For use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Mark One) x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, For use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive

3838 West Parkway Blvd. Salt Lake City, UT 84120 [email protected] NYSE: USNA USANA.com USANAHEALTHSCIENCES @USANAinc @USANAHealthSciences U S A N A H E A L T H S C IE N C E S , IN C . | A N N U A L R E P O R T 2 0 2 4 Since 1992 EXCELL

3838 West Parkway Blvd. Salt Lake City, UT 84120 [email protected] NYSE: USNA USANA.com USANAHEALTHSCIENCES @USANAinc @USANAHealthSciences U S A N A H E A L T H S C IE N C E S , IN C . | A N N U A L R E P O R T 2 0 2 4 Since 1992 EXCELLENCE HEALTH INTEGRITY COMMUNITY 20 24 annual report MISSION STATEMENT To improve lives around the world by providing the highest quality, science-back

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Mark One) x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, For use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive

Description of Securities

Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 USANA Health Sciences, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. As used in this summary, the terms “USANA,” “the Company,” “we,” “our” and

Subsidiaries of the Registrant (filed herewith).

EXHIBIT 21 SUBSIDIARIES Set forth below is a list of all active subsidiaries of the Registrant, the state or other jurisdiction of incorporation or organization of each, and the names under which subsidiaries do business as of March 7, 2025.

SANA Insider Trading Policy (filed

USANA HEALTH SCIENCES, INC. Insider Trading and Confidentiality Policy Updated: February 2024 •This Policy prohibits any disclosure of or trading on material, nonpublic information •You must report any suspected or actual violations of this Policy •Violations of this Policy may lead to disciplinary action, including termination, and subject the individuals involved to civil and criminal penalties

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 28, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 23, 2024 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commis

HIYA HEALTH PRODUCTS, LLC Financial Statements September 30, 2024 and December 31, 2023 With Independent Auditor’s Report Hiya Health Products, LLC Table of Contents September 30, 2024 and December 31, 2023 Independent Auditor’s Report 1-2 Financial

HIYA HEALTH PRODUCTS, LLC Financial Statements September 30, 2024 and December 31, 2023 With Independent Auditor’s Report Hiya Health Products, LLC Table of Contents September 30, 2024 and December 31, 2023 Independent Auditor’s Report 1-2 Financial Statements Balance Sheets 3 Statements of Operations 4 Statements of Changes in Members’ Equity 5 Statements of Cash Flows 6 Notes to Financial Statem

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On December 23, 2024, USANA Health Sciences, Inc. (“USANA” or “the Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among USANA, Karate Merger Sub, LLC, a Delaware limited liability company and a wholly-owned subsidiary of USANA (“Merger Sub”), Hiya Health Products, LLC, a Delaware limite

USANA Health Sciences Reports Fourth Quarter and Full Year 2024 Results and Provides Fiscal Year 2025 Outlook

USANA Health Sciences Reports Fourth Quarter and Full Year 2024 Results and Provides Fiscal Year 2025 Outlook SALT LAKE CITY, February 25, 2025 (BUSINESS WIRE)—USANA Health Sciences, Inc.

$920 million to $1.0 billion

USANA Health Sciences, Inc. February 25, 2025 Q4 2024 Management Commentary The Company completed the acquisition of a 78.8% controlling ownership stake of Hiya Health Products, LLC (“Hiya”) on December 23, 2024. Consequently, the Company’s fourth quarter and fiscal year 2024 include the effect of less than a week of Hiya’s operating results, which were not significant to the Company’s consolidate

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 25, 2025 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissi

Agreement and Plan of Merger dated December 23, 2024 by and among USANA Health Sciences, Inc., Karate Merger Sub, LLC, Hiya Health Products, LLC, and Shareholder Representative Services LLC (incorporated by reference to the Company’s Current Report on Form 8-K, filed December 23, 2024, Exhibit 2.1, File No. 001-35024).

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER DATED AS OF DECEMBER 23, 2024 BY AND AMONG HIYA HEALTH PRODUCTS, LLC, USANA HEALTH SCIENCES, INC., KARATE MERGER SUB, LLC AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, AS THE SELLERS’ REPRESENTATIVE Table of Contents Page ARTICLE II THE MERGER; CLOSING 19 Section 2.1 The Merger 20 Section 2.2 Organizational Documents of the Surviving Company; Managers and Of

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 23, 2024 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissi

USANA Health Sciences Announces Strategic Acquisition of Hiya Health

USANA Health Sciences Announces Strategic Acquisition of Hiya Health Hiya is a fast-growing, emerging leader of high-quality children’s health & wellness products.

Amended and Restated Limited Liability Company Agreement of Hiya Health Products, LLC dated December 23, 2024.

Exhibit 10.1 AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT OF HIYA HEALTH PRODUCTS, LLC This Amended and Restated Limited Liability Company Agreement of Hiya Health Products, LLC (the “Agreement”), is entered into on December 23, 2024, and to be effective as of the Effective Time, by and among Hiya Health Products, LLC, a Delaware limited liability company (the “Company”), each of the P

Hiya Health | Acquisition Overview NYSE: USNA December 2024 Disclaimer Forward-Looking Statements. This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchang

Hiya Health | Acquisition Overview NYSE: USNA December 2024 Disclaimer Forward-Looking Statements.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 28, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

*Third Amendment to Second Amended and Restated Credit Agreement, dated as of August 28, 2024

Exhibit 10.23 THIRD AMENDMENT TO CREDIT AGREEMENT THIS THIRD AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of August 29, 2024, is by and among USANA HEALTH SCIENCES, INC., a Utah corporation (the “Borrower”), the Guarantors party hereto, the Lenders party hereto and BANK OF AMERICA, N.A., as administrative agent (in such capacity, the “Administrative Agent”

USANA Health Sciences Reports Third Quarter 2024 Results

USANA Health Sciences Reports Third Quarter 2024 Results SALT LAKE CITY, October 22, 2024 (BUSINESS WIRE)—USANA Health Sciences, Inc.

Fiscal Year 2024 Outlook

USANA Health Sciences, Inc. October 22, 2024 Q3 2024 Management Commentary Key Financial & Operating Results •Third quarter net sales were $200 million versus $213 million during Q3 2023. •Third quarter diluted EPS was $0.56 as compared with $0.59 during Q3 2023. •Company updates fiscal year 2024 net sales and diluted EPS outlook to approximately $850 million and $2.45, respectively (previously $8

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 22, 2024 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 29, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Fiscal Year 2024 Outlook

USANA Health Sciences, Inc. July 23, 2024 Q2 2024 Management Commentary Key Financial & Operating Results •Second quarter net sales were $213 million versus $238 million during Q2 2023. •Second quarter diluted EPS was $0.54 as compared with $0.89 during Q2 2023. •Company updates fiscal year 2024 net sales and diluted EPS outlook to $850 million to $880 million and $2.40 to $2.55 (previously $850 m

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 23, 2024 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission F

USANA Health Sciences Reports Second Quarter 2024 Results

USANA Health Sciences Reports Second Quarter 2024 Results SALT LAKE CITY, July 23, 2024 (BUSINESS WIRE)—USANA Health Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35024 A. Full title of the plan and the add

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2024 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Fiscal Year 2024 Outlook

USANA Health Sciences, Inc. April 30, 2024 Q1 2024 Management Commentary Key Financial & Operating Results •First quarter net sales were $228 million versus $248 million during Q1 2023, and increased 2% sequentially in constant currency. •First quarter diluted EPS was $0.86 as compared with $0.95 during Q1 2023. •Company reiterates fiscal year 2024 net sales and diluted EPS outlook of $850 million

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 30, 2024 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission

USANA Health Sciences Reports First Quarter 2024 Results

USANA Health Sciences Reports First Quarter 2024 Results SALT LAKE CITY, April 30, 2024 (BUSINESS WIRE)—USANA Health Sciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Mark One) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Mark One) x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, For use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive

Subsidiaries of the Registrant, as of February 24, 2024 (filed herewith).

EXHIBIT 21 SUBSIDIARIES Set forth below is a list of all active subsidiaries of the Registrant, the state or other jurisdiction of incorporation or organization of each, and the names under which subsidiaries do business as of February 23, 2024.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35

USANA Health Sciences, Inc. Clawback Policy (filed herewith).

EXHIBIT 97 CLAWBACK POLICY 1.Introduction. The Board of Directors (the “Board”) of USANA Health Sciences, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this p

USNA / USANA Health Sciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv02181-usanahealthsciencesi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: USANA Health Sciences Inc Title of Class of Securities: Common Stock CUSIP Number: 90328M107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 6, 2024 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

Consolidated Results

Exhibit 99.2 USANA Health Sciences, Inc. February 6, 2024 Q4 2023 Management Commentary Key Financial Results & Guidance • Fourth quarter net sales were $221 million versus $228 million during Q4 2022 and $213 million during Q3 2023. • Fourth quarter diluted EPS was $0.87 as compared with $0.66 during Q4 2022. • Fiscal year 2023 net sales were $921 million as compared with $999 million during fisc

USANA Health Sciences Reports Fourth Quarter and Fiscal Year 2023 Results

Exhibit 99.1 USANA Health Sciences Reports Fourth Quarter and Fiscal Year 2023 Results SALT LAKE CITY-(BUSINESS WIRE)-February 6, 2024-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended December 30, 2023. Key Financial Results & Guidance Fourth quarter net sales were $221 million versus $228 million during Q4 2022 and $213

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

USANA Health Sciences Reports Third Quarter 2023 Results

Exhibit 99.1 USANA Health Sciences Reports Third Quarter 2023 Results SALT LAKE CITY-(BUSINESS WIRE)-October 24, 2023-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended September 30, 2023. Key Financial & Operating Results Third quarter net sales were $213 million versus $233 million during Q3 2022. Third quarter diluted EPS was $0.59 as c

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 24, 2023 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

Consolidated Results

Exhibit 99.2 USANA Health Sciences, Inc. October 24, 2023 Q3 2023 Management Commentary Key Financial & Operating Results • Third quarter net sales were $213 million versus $233 million during Q3 2022. • Third quarter diluted EPS was $0.59 as compared with $0.78 during Q3 2022. • Company narrows fiscal year 2023 net sales and diluted EPS outlook to $900 million to $920 million and $2.80 to $3.05,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 1, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001

USANA Health Sciences Reports Second Quarter Net Sales of $238 Million and Diluted EPS of $0.89

Exhibit 99.1 USANA Health Sciences Reports Second Quarter Net Sales of $238 Million and Diluted EPS of $0.89 SALT LAKE CITY-(BUSINESS WIRE)-July 25, 2023-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended July 1, 2023. Key Financial & Operating Results Second quarter net sales were $238 million versus $264 million during the second quarte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 25, 2023 USANA HEALTH SCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 25, 2023 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission F

Consolidated Results

Exhibit 99.2 USANA Health Sciences, Inc. July 25, 2023 Q2 2023 Management Commentary Key Financial & Operating Results • Second quarter net sales were $238 million versus $264 million during the second quarter of 2022. • Second quarter diluted EPS was $0.89 as compared with $1.00 during the second quarter of 2022. • Fiscal 2023 net sales and diluted EPS guidance updated to $900 to $950 million and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35024 A. Full title of the plan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) _______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-05

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 1, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

USANA Health Sciences Announces Plans to Expand into India

Exhibit 99.1 USANA Health Sciences Announces Plans to Expand into India SALT LAKE CITY-(BUSINESS WIRE)-May 4, 2023-USANA Health Sciences, Inc. (NYSE: USNA) today announced its plans to expand into India in the second half of 2023. Expansion into India increases the Company’s global footprint to 25 markets. “USANA’s expansion into India is our first new market in five years and provides an exciting

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2023 USANA HEALTH SCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2023 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission Fil

USANA Health Sciences Reports First Quarter Net Sales of $248 Million and Diluted EPS of $0.95

Exhibit 99.1 USANA Health Sciences Reports First Quarter Net Sales of $248 Million and Diluted EPS of $0.95 SALT LAKE CITY-(BUSINESS WIRE)-April 25, 2023-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 1, 2023. Key Financial & Operating Results First quarter net sales were $248 million versus $228 million for the fourth quarter of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 25, 2023 USANA HEALTH SCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 25, 2023 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission

2

Exhibit 99.2 USANA Health Sciences, Inc. April 25, 2023 Q1 2023 Management Commentary Key Financial & Operating Results ● First quarter net sales were $248 million versus $228 million for the fourth quarter of 2022 and $273 million during the first quarter of 2022. ● First quarter diluted EPS was $0.95 as compared with $0.66 for the fourth quarter of 2022 and $1.15 during the first quarter of 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, For Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35

Subsidiaries of the Registrant, as of February 24, 2024 (filed herewith).

EXHIBIT 21 SUBSIDIARIES Set forth below is a list of all active subsidiaries of the Registrant, the state or other jurisdiction of incorporation or organization of each, and the names under which subsidiaries do business as of February 24, 2023.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 13, 2023 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissi

USANA Health Sciences Announces CEO Transition Plan

Exhibit 99.1 USANA Health Sciences Announces CEO Transition Plan SALT LAKE CITY-(BUSINESS WIRE)-February 13, 2023-USANA Health Sciences, Inc. (NYSE: USNA) today announced that consistent with the Company’s planned succession strategy, Kevin Guest, USANA’s Chief Executive Officer (CEO) since 2015 and Chairman of the Board since 2020, will transition to the role of Executive Chairman of the Company,

USNA / USANA Health Sciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv02152-usanahealthsciencesi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: USANA Health Sciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 90328M107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 7, 2023 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

USANA Health Sciences Reports Fourth Quarter and Fiscal Year 2022 Results

Exhibit 99.1 USANA Health Sciences Reports Fourth Quarter and Fiscal Year 2022 Results SALT LAKE CITY-(BUSINESS WIRE)-February 7, 2023-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal fourth quarter and full year ended December 31, 2022. Key Financial & Operating Results Fourth quarter net sales were $228 million versus $267 million during the prior-year pe

Consolidated Results

Exhibit 99.2 USANA Health Sciences, Inc. February 7, 2023 Q4 2022 Management Commentary Key Financial & Operating Results • Fourth quarter net sales were $228 million versus $267 million during the prior-year period. • Fourth quarter diluted EPS was $0.66 as compared with $1.03 during Q4 2021. • Fiscal year 2022 net sales were $999 million as compared with $1,186 million during fiscal year 2021. •

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 5, 2023 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission

USANA Health Sciences Provides Preliminary Fiscal Year 2022 Results and Issues Initial Fiscal Year 2023 Outlook

Exhibit 99.1 USANA Health Sciences Provides Preliminary Fiscal Year 2022 Results and Issues Initial Fiscal Year 2023 Outlook SALT LAKE CITY-(BUSINESS WIRE)-January 5, 2023-USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary fiscal year 2022 results and initial guidance for fiscal year 2023 ahead of its presentation at the 25th Annual ICR Conference. The Company currently anticipat

(incorporated by reference to the Company's Quarterly Report on Form 10-Q for the period ended

EXHIBIT 10.22 SECOND AMENDMENT TO CREDIT AGREEMENT THIS SECOND AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this ?Amendment?), dated as of August 10, 2022, is by and among USANA HEALTH SCIENCES, INC., a Utah corporation (the ?Borrower?), the Guarantors party hereto, the Lenders party hereto and BANK OF AMERICA, N.A., as administrative agent (in such capacity, the ?Administrative Agen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 1, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 25, 2022 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

Consolidated Results

Exhibit 99.2 USANA Health Sciences, Inc. October 25, 2022 Q3 2022 Management Commentary Key Financial & Operating Results ? Third quarter net sales were $233 million as compared with $274 million during the third quarter of the prior year. ? Third quarter diluted EPS totaled $0.78 versus $1.36 during the third quarter of 2021. ? Company revises fiscal 2022 net sales and diluted EPS outlook to $955

USANA Health Sciences Reports Third Quarter Results

Exhibit 99.1 USANA Health Sciences Reports Third Quarter Results SALT LAKE CITY-(BUSINESS WIRE)-October 25, 2022-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended October 1, 2022. Key Financial & Operating Results Third quarter net sales were $233 million as compared with $274 million during the third quarter of the prior year. Third quar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

? Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

J. Scott Nixon, CPA Rejoins USANA Health Sciences’ Board of Directors

Exhibit 99.1 J. Scott Nixon, CPA Rejoins USANA Health Sciences? Board of Directors SALT LAKE CITY-(BUSINESS WIRE)-July 27, 2022-USANA Health Sciences, Inc. (NYSE: USNA) today announced that J. Scott Nixon, CPA has rejoined the Company?s Board of Directors effective July 25, 2022. Mr. Nixon previously served as an independent director of the Company from October 2017 through May 2019, before depart

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 25, 2022 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission F

Consolidated Results

Exhibit 99.2 USANA Health Sciences, Inc. July 26, 2022 Q2 2022 Management Commentary Key Financial & Operating Results ? Second quarter net sales were $264 million as compared with $337 million during the second quarter of the prior year. ? Second quarter diluted EPS totaled $1.00 versus $1.87 during the second quarter of 2021. ? Company reiterates fiscal 2022 net sales and diluted EPS outlook of

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 26, 2022 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission F

USANA Health Sciences Reports Second Quarter Results

Exhibit 99.1 USANA Health Sciences Reports Second Quarter Results SALT LAKE CITY-(BUSINESS WIRE)-July 26, 2022-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended July 2, 2022. Key Financial & Operating Results Second quarter net sales were $264 million as compared with $337 million during the second quarter of the prior year. Second quart

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 6, 2022 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission Fi

USANA Health Sciences Provides Preliminary Second Quarter Results and Updates Fiscal Year 2022 Outlook

Exhibit 99.1 USANA Health Sciences Provides Preliminary Second Quarter Results and Updates Fiscal Year 2022 Outlook SALT LAKE CITY-(BUSINESS WIRE)-July 6, 2022-USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary results for the second quarter ended July 2, 2022, and provided an updated outlook for fiscal year 2022. The Company anticipates that second quarter 2022 net sales will be

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35024 A. Full title of the plan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

? Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2022 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission Fi

Amendment No. 1 to USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan

EXHIBIT 10.21 AMENDMENT NO. 1 TO USANA HEALTH SCIENCES, INC. 2015 EQUITY INCENTIVE AWARD PLAN This Amendment No. 1 (the ?Amendment?) to the USANA Health Sciences, Inc. 2015 Equity Incentive Award Plan (the ?Plan?) is entered into effective the 7th day of February 2022. WHEREAS, the Plan was duly adopted by the Board of Directors (the ?Board?) of USANA Health Sciences, Inc. (the ?Company?) on March

USANA Health Sciences Reports First Quarter Results

Exhibit 99.1 USANA Health Sciences Reports First Quarter Results SALT LAKE CITY-(BUSINESS WIRE)-April 26, 2022-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 2, 2022. Key Financial & Operating Highlights First quarter net sales were $273 million as compared with $308 million during the first quarter of the prior year. First quart

Consolidated Results

Exhibit 99.2 USANA Health Sciences, Inc. April 26, 2022 Q1 2022 Management Commentary Key Financial & Operating Highlights ? First quarter net sales were $273 million as compared with $308 million during the first quarter of the prior year. ? First quarter diluted EPS totaled $1.15 versus $1.45 during the first quarter of 2021. ? Company revises fiscal 2022 net sales and diluted EPS outlook to $1.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 26, 2022 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.? ) Filed by the Registrant ? ? ? ? ? Filed by a Party other than the Registrant ?? ? ? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, For Use of the Commission Only (as perm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.? ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 1, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3502

USNA / USANA Health Sciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: USANA Health Sciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 90328M107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is f

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 8, 2022 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

USANA Health Sciences Reports Fiscal Year and Fourth Quarter 2021 Results

Exhibit 99.1 USANA Health Sciences Reports Fiscal Year and Fourth Quarter 2021 Results SALT LAKE CITY-(BUSINESS WIRE)-February 8, 2022-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its full year and fiscal fourth quarter ended January 1, 2022. Key Financial & Operating Highlights Fiscal year 2021 net sales grew 5% to $1.186 billion. Reported fiscal year 2021 dilute

USANA Health Sciences, Inc. February 8, 2022

Exhibit 99.2 USANA Health Sciences, Inc. February 8, 2022 Q4 2021 Management Commentary Key Financial & Operating Highlights ? Fiscal year 2021 net sales grew 5% to $1.186 billion. ? Reported fiscal year 2021 diluted EPS totaled $5.73. ? Fourth quarter net sales reached $267 million and diluted EPS were $1.03. ? Company provides initial 2022 net sales guidance of $1.125 to $1.225 billion and initi

USNA / USANA Health Sciences, Inc. / WENTZ MYRON W - SCHEDULE 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* USANA Health Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90328M107 (CUSIP Number) Dr. Myron W. Wentz c/o USANA Health Sciences, Inc. 3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Name, Address and

USANA Health Sciences, Inc. Deferred Compensation Plan Adoption Agreement (incorporated by reference to the Company's Quarterly Report on Form 10-Q for the period ended October 2, 2021, filed November 10, 2021, Exhibit 10.19, File No. 001-35024)*

EXHIBIT 10.20 NOTE: Execution of this Adoption Agreement creates a legal liability of the Employer with significant tax consequences to the Employer and Participants. Principal Life Insurance Company disclaims all liability for the legal and tax consequences which result from the elections made by the Employer in this Adoption Agreement. Nothing set forth in this agreement or related documents may

USANA Health Sciences, Inc. Deferred Compensation Plan (incorporated by reference to the Company's Quarterly Report on Form 10-Q for the period ended October 2, 2021, filed November 10, 2021, Exhibit 10.19, File No. 001-35024)*

EXHIBIT 10.19 Nonqualified Plan Service and Expense Agreement This Agreement is made by and between the undersigned Plan Representative (?you?, ?your?) and the undersigned member company of the Principal Financial Group? (?we?, ?us?, ?our?). You and we are the ?Parties? to this Agreement. Each of the Parties may be referred to separately as a ?Party?. This Agreement consists of this page, the foll

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

? Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 26, 2021 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

Consolidated Results

Exhibit 99.2 USANA Health Sciences, Inc. October 26, 2021 Q3 2021 Management Commentary Key Financial & Operating Highlights ? Net sales of $274.4 million as compared with $298.5 million in Q3 2020. ? Diluted EPS of $1.36 versus $1.44 during Q3 2020. ? Reiterates fiscal 2021 net sales and diluted EPS outlook provided on September 16, 2021. ? Company expects to generate approximately $130 million o

USANA Health Sciences Reports Third Quarter Results

Exhibit 99.1 USANA Health Sciences Reports Third Quarter Results SALT LAKE CITY-(BUSINESS WIRE)-October 26, 2021-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended October 2, 2021, which were modestly ahead of the preliminary outlook the Company provided on September 16, 2021. Key Financial & Operating Highlights Third quarter net sales we

Xia Ding Named to USANA Health Sciences’ Board of Directors

Exhibit 99.1 Xia Ding Named to USANA Health Sciences? Board of Directors SALT LAKE CITY-(BUSINESS WIRE)-October 12, 2021-USANA Health Sciences, Inc. (NYSE: USNA) today announced the appointment of Xia Ding to the company?s board of directors effective October 11, 2021. Ms. Ding currently serves as Vice President of e-commerce Asia Pacific and Latin America at Nike and is well-regarded as an e-comm

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 11, 2021 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 16, 2021 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commiss

USANA Health Sciences Provides Preliminary Third Quarter Results and Updates Fiscal Year 2021 Outlook; Increases Share Repurchase Authorization

Exhibit 99.1 USANA Health Sciences Provides Preliminary Third Quarter Results and Updates Fiscal Year 2021 Outlook; Increases Share Repurchase Authorization SALT LAKE CITY-(BUSINESS WIRE)-September 16, 2021-USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary third quarter results and updated outlook for fiscal year 2021. The Company currently anticipates third quarter 2021 net sal

Attachment I

VIA EDGAR August 25, 2021 Mr. Gary Newberry Staff Accountant Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: USANA Health Sciences, Inc. Form 10-K for the Fiscal Year Ended January 2, 2021 Filed March 2, 2021 File No. 001-35024 Dear Mr. Newberry: On behalf of USANA Health Sciences, Inc. (the ?Company? or ?USANA?), I am writing to respond to your letter dated August

USNA / USANA Health Sciences, Inc. / WENTZ MYRON W - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* USANA Health Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90328M107 (CUSIP Number) Dr. Myron W. Wentz c/o USANA Health Sciences, Inc. 3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Name, Address and T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 3, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 26, 2021 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission F

USANA Health Sciences, Inc. July 27, 2021

Exhibit 99.2 USANA Health Sciences, Inc. July 27, 2021 Q2 2021 Management Commentary ? Second quarter net sales increased 30.1% year-over-year to a record $336.8 million. ? Second quarter diluted EPS increased 41.7% year-over-year to $1.87. ? Active Customers increased 8.8% year-over-year to a record 652,000. ? Reiterates full-year 2021 net sales and EPS growth outlook. Overview Strong second quar

USANA Health Sciences Reports Record Second Quarter Results and Reiterates Growth Outlook for FY 2021

Exhibit 99.1 USANA Health Sciences Reports Record Second Quarter Results and Reiterates Growth Outlook for FY 2021 SALT LAKE CITY-(BUSINESS WIRE)-July 27, 2021-USANA Health Sciences, Inc. (NYSE: USNA) today announced record financial results for its fiscal second quarter ended July 3, 2021. Key Financial & Operating Highlights Second quarter net sales increased 30.1% year-over-year to a record $33

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 27, 2021 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35024 A. Full

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2021 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission Fi

Quarterly Report - FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 3, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

First Amendment to the Second Amended and Restated Credit Agreement dated as of April 21, 2021 (incorporated by reference to the Company's Quarterly report on Form 10-Q for the period ended April 3, 2021, Filed May 11, 2021, Exhibit 10.18, File No. 001-35024)

EXHIBIT 10.18 FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this ?Amendment?), dated as of April 21, 2021, is by and among USANA HEALTH SCIENCES, INC., a Utah corporation (the ?Borrower?), the Guarantors party hereto, the Lenders party hereto and BANK OF AMERICA, N.A., as administrative agent (in such capacity, the ?Administrative Agent?)

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 27, 2021 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission

USANA Health Sciences Reports First Quarter Results

Exhibit 99.1 USANA Health Sciences Reports First Quarter Results SALT LAKE CITY-(BUSINESS WIRE)-April 27, 2021-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 3, 2021. Key Financial & Operating Highlights First quarter net sales increased 15.5% year-over-year to $308.0 million. First quarter diluted EPS increased 17.9% year-over-y

Consolidated Results

Exhibit 99.2 USANA Health Sciences, Inc. April 27, 2021 Q1 2021 Management Commentary, Results and Outlook ? First quarter net sales increased 15.5% year-over-year to $308.0 million. ? First quarter diluted EPS increased 17.9% year-over-year to $1.45. ? Repurchased 721,000 shares for $69.5 million during the quarter. ? Raises full-year 2021 net sales and EPS Outlook. Overview Our first quarter rep

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

- DEF 14A

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.? ) Filed by the Registrant ? ? ? ? ? Filed by a Party other than the Registrant ?? ? ? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, For Use of the Commission Only (as perm

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* USANA Health Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) (

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* USANA Health Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90328M107 (CUSIP Number) Dr. Myron W. Wentz c/o USANA Health Sciences, Inc. 3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Name, Address and T

Code of Ethics of USANA Health Sciences, Inc. (incorporated by reference to the Company's Annual Report on Form 10-K for the period ended January 2, 2021, filed March 2, 2021, Exhibit 14, File No. 001-35024)*

Exhibit 14 USANA HEALTH SCIENCES, INC. CODE OF ETHICS FOR DIRECTORS AND EMPLOYEES This Code of Ethics for Directors and Employees (the ?Code?) has been adopted by the Board of Directors (the ?Board?) of USANA Health Sciences, Inc. (the ?Company?). The purpose of this Code is to encourage directors, officers, and employees of the Company to conduct themselves in an ethical manner and to deter them

Annual Report - FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 2, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3502

USANA Announces Formation of Board Sustainability Committee

Exhibit 99.1 USANA Announces Formation of Board Sustainability Committee SALT LAKE CITY-(BUSINESS WIRE)-February 16, 2021-USANA (NYSE: USNA), USANA Health Sciences, Inc. today announced that its Board of Directors has formed a Sustainability Committee to oversee and advise on all matters related to corporate sustainability, including environmental, social and governance (ESG) and corporate social

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 16, 2021 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: USANA Health Sciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 90328M107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is f

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 9, 2021 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

USANA Health Sciences Finishes Strong 2020 with 14.5% Fourth Quarter Net Sales Growth and 32.6% Diluted EPS Growth

Exhibit 99.1 USANA Health Sciences Finishes Strong 2020 with 14.5% Fourth Quarter Net Sales Growth and 32.6% Diluted EPS Growth SALT LAKE CITY-(BUSINESS WIRE)-February 9, 2021-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal fourth quarter and full-year ended January 2, 2021. Key Q4 and Full Year 2020 Financial & Operating Highlights Fourth quarter net sale

Consolidated Results

Exhibit 99.2 USANA Health Sciences, Inc. February 9, 2021 Q4 2020 Management Commentary, Results and 2021 Outlook ● Fourth quarter net sales increased 14.5% year-over-year to $310.5 million. ● Fourth quarter diluted EPS increased 32.6% year-over-year to a record $1.87. ● Fiscal year net sales increased 7.0% year-over-year to $1.135 billion. ● Fiscal year diluted EPS increased 32.9% year-over-year

Quarterly Report - FORM 10-Q/A

-12-28 Q3 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 26, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis

Quarterly Report - FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 26, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition - USANA HEALTH SCIENCES, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 20, 2020 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

Consolidated Results

Exhibit 99.2 USANA Health Sciences, Inc. October 20, 2020 Q3 2020 Management Commentary, Results and Outlook ● Third quarter net sales increased 14.5% year-over-year to $298.5 million due to strong product demand and successful incentive programs. ● Diluted EPS increased 32.1% year-over-year to a record $1.44. ● Active customers increased 16.5% year-over-year to a record 650,000. ● Company raises

USANA Health Sciences Reports Strong Third Quarter Growth; Raises Full-Year 2020 Net Sales and EPS Outlook

Exhibit 99.1 USANA Health Sciences Reports Strong Third Quarter Growth; Raises Full-Year 2020 Net Sales and EPS Outlook SALT LAKE CITY-(BUSINESS WIRE)-October 20, 2020-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended September 26, 2020. Key Financial & Operating Highlights Third quarter net sales increased 14.5% year-over-year to $298.5

USANA Health Sciences Announces Appointment of John T. Fleming to Board of Directors

Exhibit 99.1 USANA Health Sciences Announces Appointment of John T. Fleming to Board of Directors SALT LAKE CITY-(BUSINESS WIRE)-September 8, 2020-USANA Health Sciences, Inc. (NYSE: USNA) today announced the appointment of John T. Fleming to the company’s board of directors effective September 4, 2020. Mr. Fleming joins the board as an independent director and brings more than fifty years of direc

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - USANA HEALTH SCIENCES, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 4, 2020 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - USANA HEALTH SCIENCES, INC. 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 25, 2020 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission

Second Amended and Restated Credit Agreement dated as of August 25, 2020 (incorporated by reference to the Company’s Current Report on Form 8-K, filed August 27, 2020, Exhibit 10.1, File No. 001-35024).

Exhibit 10.1 Published CUSIP Number: [] SECOND AMENDED AND RESTATED CREDIT AGREEMENT Dated as of August 25, 2020 among USANA HEALTH SCIENCES, INC., a Utah corporation, as the Borrower, CERTAIN SUBSIDIARIES OF THE BORROWER PARTY HERETO, as the Guarantors, BANK OF AMERICA, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, and THE LENDERS PARTY HERETO and BOFA SECURITIES, INC., as Sole

Security and Pledge Agreement, dated as of August 25, 2020, by and among USANA Health Sciences, Inc. and certain of its subsidiaries, and Bank of America, N.A.

Exhibit 10.2 SECURITY AND PLEDGE AGREEMENT THIS SECURITY AND PLEDGE AGREEMENT (this “Agreement”) is entered into as of August 25, 2020, among USANA Health Sciences, Inc., a Utah corporation (the “Borrower”), the other parties identified as “Grantors” on the signature pages hereto (together with the Borrower, each individually a “Grantor”, and collectively, the “Grantors”) and BANK OF AMERICA, N.A.

USNA / USANA Health Sciences, Inc. / WENTZ MYRON W - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* USANA Health Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90328M107 (CUSIP Number) Dr. Myron W. Wentz c/o USANA Health Sciences, Inc. 3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Name, Address and T

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 27, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

USANA Health Sciences Reports Second Quarter Results

Exhibit 99.1 USANA Health Sciences Reports Second Quarter Results SALT LAKE CITY-(BUSINESS WIRE)-July 21, 2020-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended June 27, 2020. Key Financial & Operating Highlights Continued strong demand and successful promotions combined to generate $259.0 million in net sales and $1.32 in diluted EPS du

Consolidated Results

Exhibit 99.2 USANA Health Sciences, Inc. July 21, 2020 Q2 2020 Management Commentary, Results and Outlook ● Continued strong demand and successful promotions combined to generate $259.0 million in net sales and $1.32 in diluted EPS during the quarter ● Active customers increase 7.9% vs. the prior-year quarter ● Company continued to successfully execute a virtual sales and operating strategy to del

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 21, 2020 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission F

Regulation FD Disclosure, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 24, 2020 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission F

- 11-K

.  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K  (Mark One)  [X]ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the fiscal year ended December 31, 2019  or  [ ]TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  For the transition period from to  Commission file number: 001-35024   

USNA / USANA Health Sciences, Inc. / Wentz Myron W - SCHEDULE 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* USANA Health Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90328M107 (CUSIP Number) Dr. Myron W. Wentz c/o USANA Health Sciences, Inc. 3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Name, Address and T

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2020 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission Fil

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 28, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

USANA Health Sciences Reports First Quarter Results

Exhibit 99.1 USANA Health Sciences Reports First Quarter Results SALT LAKE CITY-(BUSINESS WIRE)-April 21, 2020-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended March 28, 2020. Key Financial & Operating Highlights Global manufacturing and distribution remain fully operational. Continued consumer demand and a successful promotion combine t

Consolidated Results

Exhibit 99.2 USANA Health Sciences, Inc. April 21, 2020 Q1 2020 Management Commentary, Results and Outlook ● Global manufacturing and distribution remain fully operational. ● Continued consumer demand and a successful promotion combine to generate $266.6 million in net sales during the quarter. ● Company is following guidelines from government and health officials, to keep employees safe, includin

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 21, 2020 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission

USNA / USANA Health Sciences, Inc. DEFA14A - - DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

USNA / USANA Health Sciences, Inc. DEF 14A - - DEF 14A

Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 28, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35

USNA / USANA Health Sciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: USANA Health Sciences Inc Title of Class of Securities: Common Stock CUSIP Number: 90328M107 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is fi

USNA / USANA Health Sciences, Inc. / Wentz Myron W - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* USANA Health Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90328M107 (CUSIP Number) Dr. Myron W. Wentz c/o USANA Health Sciences, Inc. 3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Name, Address and T

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2020 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

USANA Health Sciences Announces Increased Share Repurchase Authorization To $130 Million

Exhibit 99.1 USANA Health Sciences Announces Increased Share Repurchase Authorization To $130 Million SALT LAKE CITY-(BUSINESS WIRE)-February 5, 2020-USANA Health Sciences, Inc. (NYSE: USNA) today announced that the Company’s Board of Directors has authorized up to $130 million in share repurchase authorization, which is inclusive of the $30.0 million remaining under the share repurchase authoriza

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 4, 2020 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

2

Exhibit 99.2 USANA Health Sciences, Inc. Q4 and Full-Year 2019 Management Commentary, Results and Outlook ● Fourth quarter net sales of $271.3 million ● Fourth quarter net earnings of $30.8 million, or $1.41 per share ● Fiscal year net sales of $1.061 billion ● Fiscal year net earnings of $100.5 million, or $4.41 per share ● Company provides 2020 Outlook for Net Sales between $1.03 billion and $1.

USANA Health Sciences Reports Fourth Quarter and Full-Year 2019 Results

Exhibit 99.1 USANA Health Sciences Reports Fourth Quarter and Full-Year 2019 Results Fourth quarter net sales of $271.3 million Fourth quarter net earnings of $30.8 million, or $1.41 per share Fiscal year net sales of $1.061 billion Fiscal year net earnings of $100.5 million, or $4.41 per share Company provides 2020 Outlook for Net Sales between $1.03 billion and $1.13 billion and EPS between $4.1

USANA Health Sciences Announces Retirement of Founder and Chairman, Myron W. Wentz, Ph.D., from Chairman of the Board of Directors

Exhibit 99.1 USANA Health Sciences Announces Retirement of Founder and Chairman, Myron W. Wentz, Ph.D., from Chairman of the Board of Directors SALT LAKE CITY-(BUSINESS WIRE)-December 18, 2019-USANA Health Sciences, Inc. (NYSE: USNA) today announced that the Company’s founder and Chairman of the Board of Directors, Myron W. Wentz, Ph.D., has chosen to retire from the position of Board Chairman and

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 18, 2019 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissi

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 28, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

USANA Health Sciences Announces Appointment of Timothy Wood, Ph.D., to Board of Directors and Promotion of Walter Noot to Chief Operating Officer

Exhibit 99.1 USANA Health Sciences Announces Appointment of Timothy Wood, Ph.D., to Board of Directors and Promotion of Walter Noot to Chief Operating Officer SALT LAKE CITY-(BUSINESS WIRE)-October 24, 2019-USANA Health Sciences, Inc. (NYSE: USNA) today announced the appointment of Timothy Wood, Ph.D., to the company’s board of directors effective October 23, 2019. Dr. Wood joins the board as an i

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 21, 2019 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

USANA Health Sciences Reports Third Quarter 2019 Results

Exhibit 99.1 USANA Health Sciences Reports Third Quarter 2019 Results Third quarter net sales of $260.6 million Third quarter net earnings of $24.2 million, or $1.09 per diluted share Company narrows 2019 Net Sales and EPS outlook on updated FX outlook for the year SALT LAKE CITY-(BUSINESS WIRE)-October 22, 2019-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fis

2

Exhibit 99.2 USANA Health Sciences, Inc. Q3 2019 Management Commentary, Results and Outlook ● Third quarter net sales of $260.6 million ● Third quarter net earnings of $24.2 million, or $1.09 per diluted share ● Company narrows 2019 Net Sales and EPS outlook on updated FX outlook for the year October 22, 2019 Overview The third quarter of 2019 was a successful quarter for USANA on several fronts.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 22, 2019 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissio

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 29, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

2

Exhibit 99.2 USANA Health Sciences, Inc. Q2 2019 Management Commentary, Results and Outlook • Second quarter net sales of $256.0 million • Second quarter net earnings of $21.4 million, or $0.91 per diluted share • Company reiterates 2019 Net Sales and EPS outlook provided on July 2, 2019 July 23, 2019 Overview We continued to face a challenging market environment in China, and this was the major f

USANA Health Sciences Reports Second Quarter 2019 Results

Exhibit 99.1 USANA Health Sciences Reports Second Quarter 2019 Results Second quarter net sales of $256.0 million Second quarter net earnings of $21.4 million, or $0.91 per diluted share Company reiterates 2019 Net Sales and EPS outlook provided on July 2, 2019 Conference call on July 24, 2019 at 11 a.m. ET SALT LAKE CITY-(BUSINESS WIRE)-July 23, 2019-USANA Health Sciences, Inc. (NYSE: USNA) today

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 —————— FORM 8-K —————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 23, 2019 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306

Third Amendment To Amended and Restated Credit Agreement, dated as of April 27, 2011 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the Securities and Exchange Commission on July 19, 2019 Exhibit 10.1, File No. 01-35024)

Exhibit 10.1 THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT This THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (“Amendment”) is entered into as of July 15, 2019, by USANA HEALTH SCIENCES, INC., a Utah corporation (together with its successors, “Borrower”), and BANK OF AMERICA, N.A., a national banking association (together with its successors and assigns, “Bank”). RECITALS A.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 15, 2019 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah 001-32269 20-1076777 (State or other jurisdiction of incorporation) (Commission F

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 —————— FORM 8-K —————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 2, 2019 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306

USANA Health Sciences Provides Preliminary Second Quarter Results and Updates Fiscal Year 2019 Outlook

Exhibit 99.1 USANA Health Sciences Provides Preliminary Second Quarter Results and Updates Fiscal Year 2019 Outlook SALT LAKE CITY-(BUSINESS WIRE)-July 2, 2019-USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary second quarter results and updated its outlook for fiscal year 2019. The Company anticipates that second quarter 2019 net sales will range between $253 and $256 million, c

USNA / USANA Health Sciences, Inc. 11-K - - 11-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35024 A. Full

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 30, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2019 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission Fil

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 —————— FORM 8-K —————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 30, 2019 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-050030

USANA Health Sciences Reports First Quarter 2019 Results

Exhibit 99.1 USANA Health Sciences Reports First Quarter 2019 Results Results in-line with preliminary results provided on April 2, 2019 First quarter net sales of $273.0 million First quarter net earnings of $24.2 million, or $1.01 per share Company reiterates 2019 outlook provided in early April Share repurchase authorization increased to $150 million SALT LAKE CITY-(BUSINESS WIRE)-April 30, 201

2

Exhibit 99.2 USANA Health Sciences, Inc. Q1 2019 Management Commentary, Results and Outlook ● Results in-line with preliminary results provided on April 2, 2019 ● First quarter net sales of $273.0 million ● First quarter net earnings of $24.2 million, or $1.01 per share ● Company reiterates 2019 outlook provided in early April ● Share repurchase authorization increased to $150 million April 30, 20

USANA Health Sciences Provides Preliminary First Quarter Net Sales and Updates Fiscal Year 2019 Outlook

Exhibit 99.1 USANA Health Sciences Provides Preliminary First Quarter Net Sales and Updates Fiscal Year 2019 Outlook SALT LAKE CITY-(BUSINESS WIRE)-April 2, 2019-USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary first quarter net sales and updated its outlook for fiscal year 2019. The Company anticipates that first quarter 2019 net sales will range between $270 and $273 million,

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 2, 2019 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission F

USNA / USANA Health Sciences, Inc. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

USNA / USANA Health Sciences, Inc. DEF 14A

Use these links to rapidly review the document TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed March 15, 2019, File No. 001-35024).

Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF USANA HEALTH SCIENCES, INC. SECOND AMENDED AND RESTATED BYLAWS OF USANA HEALTH SCIENCES, INC. (Effective March 14, 2019) ARTICLE I OFFICES Section 1.01 Principal Office. The principal office of USANA Health Sciences, Inc. (the “Corporation”) in the State of Utah shall be located in such location as the Corporation's Board of Directors (the "Board o

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 14, 2019 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah 001-35024 87-0500306 (State or other jurisdiction of (Commission (I.R.S. Employe

Subsidiaries of the Registrant, as of February 4, 2020 (incorporated by reference to the Company's Annual Report on Form 10-K, filed February 26, 2019, Exhibit 21, File No. 001-035024)

EXHIBIT 21 SUBSIDIARIES Set forth below is a list of all active subsidiaries of the Registrant, the state or other jurisdiction of incorporation or organization of each, and the names under which subsidiaries do business as of February 26, 2019.

Specimen Stock Certificate for Common Stock (incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the year ended December 29, 2018, filed February 26, 2019).

Exhibit 4.1 HE/ILl H SCILNCI '> USANA HEALTH SCIENCES, INC. AUTHORIZED COMMON STOCK:50,000,000 SHARES $.001 PAR VALUE INCORPORATED UNDER THE LAWS OF THE STATE OF UTAH Shares of USANA HEALTH SCIENCES,INC.Common Stock transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate is not valid until counters

Code of Ethics of USANA Health Sciences, Inc. (filed herewith)

Exhibit 14 USANA

USNA / USANA Health Sciences, Inc. 10-K (Annual Report)

Use these links to rapidly review the document TABLE OF CONTENTS Item 9B. Other Information Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 29, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECU

USNA / USANA Health Sciences, Inc. / VANGUARD GROUP INC Passive Investment

usanahealthsciencesinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: USANA Health Sciences Inc Title of Class of Securities: Common Stock CUSIP Number: 90328M107 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the app

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 —————— FORM 8-K —————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2019 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500

USANA Health Sciences Reports Record Full-Year 2018 Results

Exhibit 99.1 USANA Health Sciences Reports Record Full-Year 2018 Results Record fiscal year net sales of $1.189 billion, an increase of 13.6% Record fiscal year net earnings of $126.2 million, or $5.12 per share Fourth quarter net sales of $299.0 million, an increase of 9.5% year-over-year Fourth quarter net earnings of $32.3 million, or $1.32 per share SALT LAKE CITY-(BUSINESS WIRE)-February 5, 2

Quarter Ended

Exhibit 99.2 USANA Health Sciences, Inc. Q4 2018 Management Commentary, Results and Outlook ● Record fiscal year net sales of $1.189 billion, an increase of 13.6%, ● Record fiscal year net earnings of $126.2 million, or $5.12 per share ● Fourth quarter net sales of $299.0 million, an increase of 9.5% year-over-year ● Fourth quarter net earnings of $32.3 million, or $1.32 per share February 5, 2019

USANA Health Sciences Announces Appointment of Peggie Pelosi to Board of Directors

Exhibit 99.1 USANA Health Sciences Announces Appointment of Peggie Pelosi to Board of Directors SALT LAKE CITY-(BUSINESS WIRE)-December 19, 2018-USANA Health Sciences, Inc. (NYSE: USNA) today announced the appointment of Peggie Pelosi to the company’s board of directors effective December 19, 2018. Ms. Pelosi joins the board as an independent director and brings expertise in corporate social respo

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2018 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commissi

USNA / USANA Health Sciences, Inc. CORRESP

VIA EDGAR November 27, 2018 Ms. Keira Nakada Staff Accountant Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: USANA Health Sciences, Inc. Form 10-K for the Fiscal Year Ended December 30, 2017 Filed February 28, 2018 Form 10-Q for the Quarterly Period Ended June 30, 2018 Filed August 8, 2018 File No. 001-35024 Dear Ms. Nakada: On behalf of USANA Health Sciences, Inc

USNA / USANA Health Sciences, Inc. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 29, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

USNA / USANA Health Sciences, Inc. CORRESP

VIA EDGAR November 2, 2018 Ms. Keira Nakada Staff Accountant Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: USANA Health Sciences, Inc. Form 10-K for the Fiscal Year Ended December 30, 2017 Filed February 28, 2018 Form 10-Q for the Fiscal Quarter Ended June 30, 2018 Filed August 8, 2018 File No. 001-35024 Dear Ms. Nakada: On behalf of USANA Health Sciences, Inc. (

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 —————— FORM 8-K —————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 23, 2018 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500

USANA Health Sciences Reports Results for Third Quarter 2018; Updates 2018 Outlook; Board Increases Share Repurchase Authorization

Exhibit 99.1 USANA Health Sciences Reports Results for Third Quarter 2018; Updates 2018 Outlook; Board Increases Share Repurchase Authorization Third quarter net sales of $296.8 million, an increase of 13.4% year-over-year Third quarter diluted earnings per share increased 27.8% year-over-year to $1.24 Total Active Customers increased 9.2% year-over-year to 615,000 Board increases share repurchase

2

Exhibit 99.2 October 23, 2018 Overview USANA Health Sciences, Inc. Q3 2018 Management Commentary, Results and Outlook ● Third quarter net sales of $296.8 million, an increase of 13.4% year-over-year ● Third quarter diluted earnings per share increased 27.8% year-over-year to $1.24 ● Total Active Customers increased 9.2% year-over-year to 615,000 ● Company updates 2018 growth outlook ● Board increa

USNA / USANA Health Sciences, Inc. / Wentz Myron W - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* USANA Health Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90328M107 (CUSIP Number) Dr. Myron W. Wentz c/o USANA Health Sciences, Inc. 3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Name, Address and T

USNA / USANA Health Sciences, Inc. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

USNA / USANA Health Sciences, Inc. / Wentz Myron W - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* USANA Health Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90328M107 (CUSIP Number) Dr. Myron W. Wentz c/o USANA Health Sciences, Inc. 3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Name, Address and T

2

Exhibit 99.2 USANA Health Sciences, Inc. Q2 2018 Management Commentary, Results and Outlook ● Record quaterly net sales of $301.5 million, an increase of 17.3% year-over-year ● Record quaterly net earnings of $33.9 million, or $1.36 per diluted share ● Company increases 2018 outlook July 24, 2018 Overview The second quarter of 2018 was another exceptional quarter for USANA. We reported record quar

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 —————— FORM 8-K —————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 24, 2018 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306

USANA Health Sciences Reports Record Results for Second Quarter 2018; Increases 2018 Outlook

Exhibit 99.1 USANA Health Sciences Reports Record Results for Second Quarter 2018; Increases 2018 Outlook Record second quarter net sales of $301.5 million, an increase of 17.3% year-over-year Second quarter diluted earnings per share increased 46.2% year-over-year to $1.36 per share SALT LAKE CITY-(BUSINESS WIRE)-July 24, 2018-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial res

USNA / USANA Health Sciences, Inc. 11-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35024 A. Full

USNA / USANA Health Sciences, Inc. / Wentz Myron W - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* USANA Health Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90328M107 (CUSIP Number) Dr. Myron W. Wentz 3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Name, Address and Telephone Number of Person Author

USNA / USANA Health Sciences, Inc. / Wentz Myron W - SCHEDULE 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* USANA Health Sciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90328M107 (CUSIP Number) Dr. Myron W. Wentz 3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Name, Address and Telephone Number of Person Author

USNA / USANA Health Sciences, Inc. / Wentz Myron W - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) USANA HEALTH SCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 90328M107 (CUSIP Number) December 31, 2008** (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate

USNA / USANA Health Sciences, Inc. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2018 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission Fil

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 24, 2018 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission

2

Exhibit 99.2 USANA Health Sciences, Inc. Q1 2018 Management Commentary, Results and Outlook ● Record first quarter net sales of $292.0 million, an increase of 14.4% year-over-year ● First quarter net earnings of $28.9 million, or $1.19 earnings per share ● Company increases 2018 outlook April 24, 2018 Overview The first quarter of 2018 was a solid start to what we expect to be another exceptional

USANA Health Sciences Reports Record First Quarter 2018 Net Sales and Increases 2018 Outlook

Exhibit 99.1 USANA Health Sciences Reports Record First Quarter 2018 Net Sales and Increases 2018 Outlook Record first quarter net sales of $292.0 million, an increase of 14.4% year-over-year First quarter diluted earnings per share increased 38.4% to $1.19 per share SALT LAKE CITY-(BUSINESS WIRE)-April 24, 2018-USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fis

USNA / USANA Health Sciences, Inc. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

USNA / USANA Health Sciences, Inc. DEF 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14